ADMA Biologics Inc Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseases Moderna, Inc. (NASDAQ: MRNA ) announced four initiatives to advance mRNA vaccines to prevent infectious diseases. They include its global public health portfolio to 15 vaccine programs and setting up the mRNA Access to provide its mRNA technology to researchers to explore new vaccines against emerging or neglected infectious diseases. Additionally, the company said it has resolved not to enforce its COVID patents in the Gavi COVAX AMC for 92 low- and middle-income countries. The company also said, with the assistance of the U.S. government, it has entered into a memorandum of understanding with Kenya to establish Kenya as the location for its mRNA manufacturing facility. Mallinckrodt Agrees To Pay $234M To Settle Lawsuit Alleging Underpayment Of Medicaid Drug Rebates Mallinckrodt plc (OTC: MNKKQ ) has agreed to pay $234 million to settle false claims act case brought by Whistleblower Law Collaborative regarding underpayment of Medicaid rebates for its drug Acthar.

FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by y

ADMA Biologics Inc. (NASDAQ:ADMA) price is hovering higher on Wednesday, March 02, jumping 0.91% above its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at today’s price movement shows that the recent level at last check reads $1.64, with intraday deals fluctuating between … Investors Cash In On ADMA Biologics Inc.’s 0.91% Gain Read More »

Adma Biologics (ADMA) activist holder Caligan Partners is said to be supportive of the company''s ongoing strategic review

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH) announced an upward revision

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception

ADMA Biologics Inc (NASDAQ: ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million.  The preliminary results represe

FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 FDA approval positions Company to meet or exceed target of ten or more FD

ADMA Biologics: 2021 Was Tough

ADMA Biologics (NASDAQ: ADMA) recently received a number of ratings updates from brokerages and research firms: 12/22/2021 ADMA Biologics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a $1.50 price target on the stock. According to Zacks, ADMA Biologics, Inc. is a specialty []

Zacks Investment Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $1.50 price objective on the biotechnology companys stock. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and []